On March 8, 2019, Tian Baoguo, deputy director of the Ministry of Science and Technology of the Ministry of Science and Technology, inspected the progress of the bio-industry development of Wuhan Optics Valley Bio City. As a representative , Wuhan Bio-Raid Biotechnology Co., Ltd. made a special report. Wu Linzhang, deputy director of Hubei Science and Technology Department, Li Jize, director of Wuhan Science and Technology Bureau, Feng Li, chief engineer of Donghu High-tech Zone Management Committee, and Ni Hongwei, president of Wuhan University of Science and Technology, They accompanied the inspection.

Zhang Tongcun, the chairman of the company, introduced the progress of the immune cell therapy technology, clinical application and future development vision of the company to the researcher. In particular, CAR-T has made significant breakthroughs in clinical research for the treatment of HIV infection. Among the 8 clinical treatments that have been carried out, one of them has a clinical monitoring viral load of up to 10 months and it has reached the medical "functional cure" effect in the short term. The application of this technology can effectively activate the "latent virus database", which is a key point different from domestic and foreign technology, and will also be the hope to completely solve the global HIV problem in the future.

After listening to the introduction of the chairman, Director Tian gave a high evaluation and affirmation to the immune cell therapy technology that our company is carrying out.

Director Tian stressed that since the Prime Minister Li Keqiang’s 2017 work conference emphasized the need to seize the research and development of independent innovation technologies such as domestic cancer treatment, the state has issued a series of support policies to encourage enterprises to innovate. The Ministry of Science and Technology has also issued major special projects on the creation of new drugs, encouraged enterprises to actively declare, and use the various resources of the national open platform to give full play to the advantages of enterprises, promote clinical research and clinical trials, accelerate the creation of new drugs, and help the country solve tumors and other  major diseases’s treatment 

The company said that our CAR-T technology has been fully covered in the treatment of blood tumors, and the realization of new drug listing is the focus of the company's next development. In terms of technological innovation, the company will continue to conduct in-depth research on solid tumors, HIV, etc., advance clinical and make greater progress.

At present, the company is the largest immune cell therapy company in Central China. The clinical research has been carried out in Wuhan, Jiangsu, Guangxi and other places, with a total of 400 cases. The new 6000 square meters production workshop has also reached the scale and requirements of GMP drug production. In the future, the enterprise will give full play to the leading role of the industry, continuously improve their technological innovation capabilities, realize the listing of new drugs as soon as possible, and make more contributions to promoting regional economic development.